Galectin Therapeutics

OverviewSuggest Edit

Galectin Therapeutics is a biotechnology company focused on discovery and development. The Company aims to create new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Drug candidates based on its carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in the treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies.

TypePublic
Founded2001
HQNorcross, US
Websitegalectintherapeutics.com

Latest Updates

Employees (est.) (Mar 2020)7(+17%)
Share Price (Sept 2020)$2.8 (-1%)
Cybersecurity ratingAMore

Key People/Management at Galectin Therapeutics

Richard E. Uihlein

Richard E. Uihlein

Independent Director, Chairman of the Board
Harold H. Shlevin

Harold H. Shlevin

President and Chief Executive Officer, Director
Gilbert F. Amelio

Gilbert F. Amelio

Independent Director
Rex Horton

Rex Horton

Vice President, Commercial Development, Regulatory Affairs and Quality Assurance
Pol F. Boudes

Pol F. Boudes

Chief Medical Officer
Joel Lewis

Joel Lewis

Independent Director
Show more

Galectin Therapeutics Office Locations

Galectin Therapeutics has an office in Norcross
Norcross, US (HQ)
4960 Peachtree Industrial Blvd #240
Show all (1)

Galectin Therapeutics Financials and Metrics

Galectin Therapeutics Revenue

USD

Net income (Q2, 2020)

(6.1m)

EBIT (Q2, 2020)

(6.1m)

Market capitalization (18-Sept-2020)

162.0m

Closing stock price (18-Sept-2020)

2.8

Cash (30-Jun-2020)

40.8m
Galectin Therapeutics's current market capitalization is $162 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

6.9m5.4m6.4m7.0m7.0m6.2m4.5m7.1m6.0m

R&D expense

3.6m4.5m5.7m8.4m13.1m15.3m11.7m6.5m7.5m

Operating expense total

10.4m9.9m12.1m15.4m20.1m21.5m16.2m13.6m13.4m

EBIT

(10.4m)(9.9m)(12.1m)(15.4m)(20.1m)(21.5m)(16.2m)(13.6m)(13.4m)
USDQ2, 2011

Financial Leverage

8.9 x
Show all financial metrics

Galectin Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Galectin Therapeutics Online and Social Media Presence

Embed Graph

Galectin Therapeutics News and Updates

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update

NASH-RX Trial Continues to Enroll New Patients NASH-RX Trial Continues to Enroll New Patients

Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update

Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galect…

Galectin Therapeutics Reports Q3 2019 Financial Results

Provides Update on NASH-RX Trial Plan Provides Update on NASH-RX Trial Plan

Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepati…

Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update

NORCROSS, Ga., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2019. These results are included in t…

Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering

NORCROSS, Ga., May 23, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported the Alternate Price (i.e., the final computed price) of the common stock and related warrant subscribed in its Rights Offer…
Show more

Galectin Therapeutics Blogs

UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this patient population Compelling NASH-RX trial result could potentially lead to accelerated FDA approval

Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis

Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis Content Import Tue, 06/30/2020 - 08:02 Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Tri…

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update Content Import Mon, 05/11/2020 - 08:01 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update 05/11/…

Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis

Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis jennifer.segal… Thu, 04/30/2020 - 09:01 Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis 04/30/20 T…

Harold Shlevin, PhD

Harold Shlevin, PhD jennifer.segal… Wed, 04/29/2020 - 14:44 Harold Shlevin, PhD Director since December 2019 Dr. Shlevin is a bioscience industry executive with 25 years of senior management experience in the development and commercialization of pharmaceuticals…

Galectin Therapeutics Update on the Impact of COVID-19

NORCROSS, Ga. , April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.
Show more

Galectin Therapeutics Frequently Asked Questions

  • When was Galectin Therapeutics founded?

    Galectin Therapeutics was founded in 2001.

  • Who are Galectin Therapeutics key executives?

    Galectin Therapeutics's key executives are Richard E. Uihlein, Harold H. Shlevin and Gilbert F. Amelio.

  • How many employees does Galectin Therapeutics have?

    Galectin Therapeutics has 7 employees.

  • Who are Galectin Therapeutics competitors?

    Competitors of Galectin Therapeutics include Vivace Therapeutics, Northwest Biotherapeutics and Merrimack Pharmaceuticals.

  • Where is Galectin Therapeutics headquarters?

    Galectin Therapeutics headquarters is located at 4960 Peachtree Industrial Blvd #240, Norcross.

  • Where are Galectin Therapeutics offices?

    Galectin Therapeutics has an office in Norcross.

  • How many offices does Galectin Therapeutics have?

    Galectin Therapeutics has 1 office.